UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  January 26, 2016 (January 20, 2016)

Nivalis Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code:  (720) 945-7700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02                                           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 20, 2016, the Compensation Committee of the Board of Directors of Nivalis Therapeutics, Inc. (the “Company”) approved the following annual base salaries for 2016 for the executive officers of the Company who are expected to be the named executive officers of the Company in the proxy statement to be filed for the Company’s 2016 annual stockholders meeting: Jon Congleton, President and Chief Executive Officer, $450,000; Janice Troha, EVP Product Development/Regulatory Affairs and Chief Operating Officer, $383,835; R. Michael Carruthers, EVP Finance and Administration and Chief Financial Officer, $357,000; Sherif Gabriel, VP Research and Discovery, $303,080; and Steven Shoemaker, VP Clinical R&D and Medical Director, $306,510.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2